Pharmacy Times

SEPTEMBER 13, 2022

Asceniv is a plasma-derived polyclonal IVIG drug product designed to prevent serious bacterial infections in patients with primary humoral immunodeficiency disease.

65

65

European Pharmaceutical Review

JUNE 23, 2023

Study data from a major trial has demonstrated RNA CAR-T (rCAR-T) therapy Descartes-08 facilitated significant and long-lasting clinical improvement in generalised myasthenia gravis (gMG). This is the first clinical trial using rCAR-T to treat autoimmunity.

Chemotherapy 98

Chemotherapy 98

PharmaShots

JUNE 20, 2023

time to IVIg retreatment, biomarker analyses of C2 levels, changes in measurements on key clinical efficacy scores & several patient-reported QoL outcome measures Ref: Globenewswire | Image: argenx Related News:- argenx Reports the US FDA Acceptance of BLA for Efgartigimod to Treat Generalized Myasthenia Gravis PharmaShots!

FDA 40

FDA 40

The Thyroid Pharmacist

JULY 7, 2023

A dosage of 200 mcg per day has been found to reduce thyroid antibodies in clinical trials. [41] Wobenzym N is the formulation that was studied; however, I’ve also seen similar clinical benefits with Wobenzym PS , Rootcology Systemic Enzymes , and Pure Encapsulations Systemic Enzyme Complex. It’s much easier to access and consume.

Immunization 102

Immunization Dosage Compounding Pharmaceutical Companies 102

Pharmaceutical Technology

JUNE 20, 2023

It involves an IVIg dependency and monitoring period, with two cohorts being dosed over 16 weeks. ARDA (NCT05225675) is a randomised, double-blind, placebo-controlled, multicentre study evaluating the effects of two dose regimens of ARGX-117 in MMN-diagnosed adults. MMN is a rare, progressive muscle disorder primarily affecting men.

Immunization 98

Immunization Communication 98